G04CB02 - Dutasteride

Probably not porphyrinogenic

Rationale

Dutasteride is not a substrate, inhibitor or inducer of CYP450 enzymes and no pharmacokinetic porphyrinogenic effects are suspected.

Chemical description

Oxosteroide

Therapeutic characteristics

Dutasteride is a testosterone 5-alpha-reductase inhibitor used in the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). It is administered orally.

Metabolism and pharmacokinetics

Dutasteride is metabolized by CYP3A4/5 (SPC). Dutasteride and its metabolites are mainly excreted in the feaces (SPC). Dutasteride does not have an effect on warfarin or digoxin and is thus not an inhibitor or inducer of CYP2C9 (SPC). In vitro interaction studies report that it is not an inhibitor of CYP1A2, 2A6, 2E1, 2C8, 2D6, 2C9, 2C19, 2B6 or 3A4 (SPC). No drug-drug interactions with dutasteride as perpetrator have been reported in the literature (Lexi-Interact, Keam 2008).

Similar drugs

Explore alternative drugs in similar therapeutic classes G04C / G04CB or go back.

References

#	Citation details	PubMed ID
1.	Dutasteride: a review of its use in the management of prostate disorders. Keam SJ, Scott LJ. Drugs. 2008; 68(4):463-85.	18318566
Government bodies
2.	Table of Substrates, Inhibitors and Inducers US Food and Drug Administration (FDA) Drug Development and Drug Interactions Access Date: 2015-August-26
Drug interaction databases
3.	Dutasteride: Drug interaction program. Lexi-Interact in UpToDate.
Summary of Product Characteristics
4.	Summary of Product Characteristics (SPC). (Avodart). The electronic Medicines Compendium (emc).